Oculus Innovative Sciences launches Alevicyn SG antipruritic spray gel for atopic dermatitis

Developed for the prescription market and formulated with the patented Microcyn Technology, the product is being made available via the company’s dermatology division IntraDerm Pharmaceuticals.

Alevicyn SG Antipruritic Gel is indicated to manage and relieve the burning, itching and pain associated with different types of dermatoses, including radiation dermatitis and atopic dermatitis.

In May this year, Oculus received FDA 510(k) clearance for the Alevicyn SG.

Oculus dermatology division IntraDerm Pharmaceuticals president Jeffrey Day said: "We’re excited about building on our dermatology portfolio of products and believe Alevicyn SG is an exciting and advanced product offering for the professional dermatology community.

"Alevicyn SG’s unique formulation is designed to help patients suffering from the effects of various inflammatory dermatoses and our Microcyn Technology has proven itself successful in both clinical studies and in daily clinical use for the resolution of various skin dermatoses, including relief of pain and itch associated with those skin afflictions."

The company’s first US dermatology products include Alevicyn Antipruritic Gel, Alevicyn Dermal Spray and Celacyn Prescription Scar Gel.

According to a 2009 GlobalData study, the global atopic dermatitis therapeutics market was estimated to have delivered revenues of $643m in 2009 and is forecast to increase to $810m at a CAGR of 3.4% by 2016.

Globally, the US remains the largest market for atopic dermatitis therapeutics, which generated revenue of $402m in 2009 and is forecast to reach $582m by 2016.